corvia®

REDUCE LAP-HF II

3-Year Responder Group Highlights

Context and key findings

REDUCE LAP-HF II is the largest device therapy trial for heart failure patients with EF≥40%. The study discovered a specific phenotype of heart failure (HF) patients who respond positively to atrial shunt therapy, termed "Responders".

Now with follow-up data spanning three years, Responders with the Corvia® Atrial Shunt continue to experience significantly fewer HF events and an improved quality of life compared to sham control.

Compared to sham

50%
Fewer patients **hospitalized**

>10 points
Greater Improvement in **KCCQ-OSS**

72%
More patients **improved ≥1 NYHA Class**

Safe
No statistically significant differences in key safety endpoints

Consistent HF event reduction through 3 years[1]

Mean cumulative heart failure events
HF hospitalizations or visits for worsening HF



% of patients with a HF hospitalization



3-year KCCQ improvement consistent across all domains[2,3]

Study data suggest the Corvia Atrial Shunt is an effective therapy for improving quality of life.



90% More Corvia Atrial Shunt patients experienced a **>20 point KCCQ-OSS** improvement by year 3 vs sham patients

NNT = 5 Treating **just 5 patients** with the Corvia Atrial Shunt yields an additional patient with a large (>20 point) 3-year KCCQ improvement

Key Safety Outcomes[1,2]

No statistically significant differences in CV mortality, stroke, or other SAEs vs sham.

Events in Responders through 3 years	Corvia Atrial Shunt (N=161)	Sham (N=152)	p-value
Cardiovascular mortality	4.4%	2.2%	0.35
Non-fatal ischemic stroke	1.9%	0.0%	0.25
Thrombo-embolic complications (TIA)	0.0%	1.5%	0.21
New or worsening kidney dysfunction	10.7%	19.3%	0.04
Newly acquired persistent or permanent atrial fibrillation or flutter	5.7%	6.7%	0.72
Myocardial infarction	2.2%	2.5%	1.00

Consider giving your HFpEF patients a new opportunity to find relief.

Learn more about our ongoing confirmatory study, RESPONDER-HF

corvia®

Corvia Medical, Inc.
One Highwood Drive, Suite 300
Tewksbury, MA 01876 USA

PS00698, MKT1024 (EU) Rev01 2025-04

CE 2797 UKCA 0086

1) Litwin, Sheldon E., et al. "Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials." American Heart Journal 278 (2024): 106-116.

2) Statistical analyses conducted by Baim Institute for Clinical Research. Data on file.

3) All subjects blinded to treatment arm for two years.

The Corvia Atrial Shunt System is indicated for the improvement in quality of life and reduction of heart failure related symptoms and events in patients with heart failure with preserved (HFpEF) or mid-range ejection fraction (HFmrEF) with elevated left atrial pressures, who remain symptomatic despite standard Guideline Directed Medical Therapy (GDMT). See the Instructions for Use for complete information regarding the procedure, indications for use, contraindications, warnings, precautions, and potential adverse events.